York, UK, 21 September 2021: The European Laboratory Research & Innovation Group (ELRIG) UK today announced it will launch its equality, diversity, and inclusion (EDI) guiding principles at Drug Discovery 2021. The principles were developed with the support of Equality, Diversity and Inclusion in Science and Health (EDIS), a coalition of organisations working to improve EDI within the science and health research sectors, and the ELRIG community. To promote the initiative, EDIS will host a series of EDI workshops at Drug Discovery 2021—a free-to-attend, in-person event which will take…
- Blackstone portfolio company BioMed Realty acquires 15-acre Cambridge International Technology Park and 27-acre plot at Granta Park in Cambridge- Estimated £850 million investment expected to deliver approximately 800,000 square feet of in-demand Grade A purpose-built lab and office space in Cambridge, creating up to 2,700 jobs- Acquisitions mark vote of confidence from Blackstone in the UK and the growth of the nation’s pioneering life sciences sector, and are supported by BioMed’s 870,000 square feet UK portfolio currently 100% fully leased
SAN DIEGO--(BUSINESS WIRE)--In a major boost to…
We have advised Tyk, a London-based global tech company, on its $35 million growth equity funding round led by new investors Scottish Equity Partners (SEP), alongside existing investors MMC Ventures. Tyk will use the funding to reach new markets and accelerate product development.
Tyk’s innovative API management solution helps to build mission-critical systems in highly regulated industries such as financial services, healthcare, and government. It is used by some of the world’s largest enterprises such as Societe Generale, Starbucks and Domino’s.
With businesses reinventing the way they…
We have advised Artificial Intelligence (AI) company Peak on its Series C funding, which raised $75 million.
This is the second round of funding for Peak in 2021, after completing a $21 million round of Series B funding in February, also advised by Taylor Wessing.
In total the company has raised $119 million, with SoftBank Vision Fund 2 leading Series C, supported by existing investors MMC Ventures, Oxx, Praetura Ventures, Arete and Octopus Ventures.
Our Corporate technology and Life sciences Partner Howard Palmer led the legal team advising on the deal with support from Senior Associate…
Arecor Therapeutics plc
(“Arecor”, the “Company” or the “Group”)
ARECOR ANNOUNCES POSITIVE HEADLINE RESULTS FROM FIRST PHASE I CLINICAL TRIAL OF
AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN CANDIDATE FOR DIABETES
AT278 delivers significantly accelerated PK/PD profile compared to NovoRapid®
Potential to be first concentrated (500U/mL) ultra-rapid acting insulin product enabling miniaturisation of next generation insulin delivery devices
Potential to enable more effective disease management for insulin resistant patients requiring >200 units of insulin per day
Cambridge, UK, 20…
LONDON, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that John H. Johnson has been appointed as non-executive chairman of its Board of Directors, effective September 15, 2021. Dr. Martin Murphy, who previously served as chairman, will continue to serve as a non-executive Board member.
Mr. Johnson brings to Autolus more than 30 years of experience in the life science industry. He is currently chief executive officer and a director of Strongbridge…
IBX, a global leader in biobanking, bioprocessing and analytics, has acquired UK based biospecimen storage specialists Roylance Pharma
“The team and capabilities within Roylance Pharma perfectly complement those within IBX. Establishing a solid biobanking and bioprocessing hub in the UK servicing Europe, reinforces not only the IBX strategy and mission but also our proposition to clients and commitment to providing world leading biomaterial services,” said Grimwood.
Benedict Roylance, Co-Founder of Roylance Pharma, said “Joining Roylance Pharma and IBX is a natural fit that will benefit both…
CY Partners are delighted to announce the opening of their new office in London over the summer. It comes on the back of several years’ growth within the southern region for this niche science recruitment firm originating from Newcastle. In the London office currently works the wonderful Neil Walton and Matt Williams with support in payroll, marketing and key account servicing coming from the wider CY Partners team. They are looking to expand imminently so get in touch if you’re interested in joining them! They have worked incredibly hard and have seen much success both before and after…
AMSBIO has launched STEM-CELLBANKER® EX - a next generation cryopreservation product that eliminates the need for the traditional washing steps required in cell therapy product development.Rapid developments in cell, tissue, and gene therapies over the last decade have redefined what a cell therapy can be. The use of living cells as the active medicinal ingredient present great opportunities to deliver treatment that can trigger the body’s own capacity to regenerate damaged or diseased tissue. However, the development of a cell therapy using a process that includes the washing out of the…
Cambridge and London, UK: 14 September 2021
One Nucleus, the non-for-profit Life Science membership group focused primarily on the Greater Cambridge and London Life Sciences Cluster aims to enable that ecosystem to accelerate the translation of great science and innovation into better patient outcomes. Supporting companies throughout their life cycle. This includes facilitating connections between entrepreneurs and company-makers, including investors. Deep Science Ventures (DSV) operate across multiple sectors combining world-leading knowledge, talent and investment to form high impact new…